Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Vemurafenib effectively controlled Chemotherapy-refractory Intrahepatic Cholangiocarcinoma with BRAF V600E Mutation: a case report and literature review.

Zeitschrift fur Gastroenterologie - 1 Dec 2022

Weng Shanshan, Zhang Ding, Yang Mengyuan, Wang Liuhong, Yuan Ying

Abstract excerpt

HINTERGRUND: Die Chemotherapie ist die erste Behandlungsoption für das lokal fortgeschrittene oder metastasierte intrahepatische Cholangiokarzinom (ICC). Nach einer Erstlinien-Chemotherapie gibt es jedoch keine Standardzweitlinienbehandlung oder zielgerichtete Wirkstoffe für diese Patienten. FALLPRäSENTATION: Hier stellen wir einen fortgeschrittenen ICC-Patienten vor, der eine radikale Entfernung und eine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mutation
Share to Proto-Oncogene Proteins B-raf

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Vemurafenib

Source

Identifiers

PMID: 35584781
DOI: 10.1055/a-1826-2814

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Vemurafenib effectively controlled Chemotherapy-refractory Intrahepatic Cholangiocarcinoma with BRAF V600E Mutation: a case report and literature review.PMID 35584781Read ↗

Intrahepatic cholangiocarcinoma: current management and emerging therapies.Semantic proximity Read ↗

BRAF V600E-mutant intrahepatic cholangiocarcinoma treated successfully with encorafenib, binimetinib, and cetuximabSemantic proximity Read ↗

Untitled literature recordSemantic proximity Read ↗

[Treatment with dabrafenib and trametinib in an intrahepatic cholangiocarcinoma harboring a BRAF V600E mutation].Semantic proximity Read ↗

Comprehensive molecular profiling of intrahepatic cholangiocarcinoma in the Chinese population and therapeutic experienceSemantic proximity Read ↗

Comprehensive molecular profiling of intrahepatic cholangiocarcinoma in the Chinese population and therapeutic experience.Semantic proximity Read ↗

Intrahepatic Cholangiocarcinoma With Extrahepatic Metastasis and High Tumor Mutation Burden: Case of Complete Pathological Response to Cisplatin/Gemcitabine/Pembrolizumab.Semantic proximity Read ↗

Complete Response for Adding Pyrotinib to Pembrolizumab and Lenvatinib for HER2 Positive Advanced Intrahepatic CholangiocarcinomaSemantic proximity Read ↗

Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges.Semantic proximity Read ↗

Durable response to sotorasib in KRAS G12C-mutant intrahepatic cholangiocarcinoma: a case report.Semantic proximity Read ↗

Complete Clinical Response of BRAF-Mutated Cholangiocarcinoma to Vemurafenib, Panitumumab, and Irinotecan.Semantic proximity Read ↗

Derazantinib: an investigational drug for the treatment of cholangiocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.